Bioequivalence Study of Two Tablet Formulations of Ramipril in Healthy Volunteers

This study was conducted in order to assess the bioequivalence of a test and reference tablet formulation containing 10 mg of ramipril ((lS,5S,7S)-8-[(2S)-2-[[(lS)-l-ethoxycarbonyl-3-phenyl-pro-pyl]amino]propanoyl]-8-azabicyclo[3.3.0] octane-7-carboxylic acid, CAS 87333-19-5). Forty healthy male and female volunteers were treated in a single-centre randomised, single-dose, open-label, 2-way crossover study, with a washout period of 35 days between treatments. Plasma samples were collected up to 168 h post-dosing for the determination of ramipril and its active metabolite, ramiprilat, by LC-MS/MS. The evaluation of bioequivalence was based on the following pharmacokinetic parameters that were calculated by standard non-com-partmental methods: the area under the plasma concentration-time curve from zero to the time of the last quantifiable concentration (AUC,) and that extrapolated to infinity (AUC) and the maximum observed concentration (C_max). The 90% confidence interval of the ratios (test/reference) (obtained by analysis of variance, ANOVA) were 0.83–1.20 for C_max of ramipril, 0.90–1.10 for C_max of ramiprilat, 0.95–1.23 for AUC_0–48 of ramipril, 0.97–1.11 for AUC_0–168 of ramiprilat, 0.96–1.23 for AUC of ramipril and 0.98–1.15 for AUC of ramiprilat, i. e. within the predefined acceptable range for the conclusion of bioequivalence. T_max of the test formulation was 0.67 ± 0.33 h for ramipril and 2.28 ± 0.74 h for ramiprilat; T_max of the reference formulation was 0.71 ± 0.32 h for ramipril and 2.40 ± 0.88 for ramiprilat. The ramipril and ramiprilat T_max values estimated for the test and the reference formulations were not significantly different (p-value > 0.05). The study indicated that the test and reference formulations containing 10 mg of ramipril were equivalent in terms of both the rate and extent of bioavailability.

Key words

Angiotensin-Converting enzyme (ACE) inhibitors - CAS 87333-19-5 - Ramipril, bioequivalence, pharmacokinetics - Ramiprilat

• References

• 1 Metzger H, Maier R, Sitter C, Stern HO. 2-[N-[(S)-l-Ethoxy-carbonyl-3-phenylpropyl]-Lalanyl]-(1S,3S,5S)-2-azabicyclo [3.3.0] octane-3-carboxylic acid (Hoe 498) - a new and highly effective angiotensin I converting enzyme inhibitor. Arzneimittelforschung. 1984; 34 (10b) 1402-6
• 2 van Griensven JMT, Schoemaker RC, Cohen AF, Luus HG, Seibert-Grafe M, Rothing HJ. Pharmacokinetics, pharma-codinamics and bioavailability of the ACE inhibitor ramipril. Eur J Clin Pharmacol. 1995; 47: 513-8
• 3 Frampton JE, Peters DH. Ramipril - an updated review of its therapeutic use in essential hypertension and heart failure. Drugs. 1995; 49 (3) 440-466
• 4 The European Agency for the Evaluation of Medicinal Products. Note for guidance on the investigation of bioavailability and bioequivalence. CPMP/EWP/QWP/1401. London; 26 July 2001.
• 5 World Medical Association Declaration of Helsinki. Ethical principles for medical research involving human subjects. 52nd WMA General Assembly; October 2000; Edinburgh, Scotland.
• 6 The European Agency for the Evaluation of Medicinal Products. Note for guidance on good clinical practice. CPMP/ICH/135/95. London; July 2002.
• 7 Guidance for Industry. Bioanalytical method validation U.S. Department of Health and Human Services. Bethesda (MD): Food and Drug Administration; May 2001.
• 8 Zhu Z, Vachareau A, Neirinck L. Liquid chromatography-mass spectrometry method for determination of ramipril and its active metabolite ramiprilat in human plasma. J Chromatog B. 2002; 779: 297-306
• 9 Lu XY, Shen-Tu JZ, Liu J. High-performance liquid chromatography-mass spectrometric analysis of ramipril and its active metabolite ramiprilat in human serum: Application to a pharmacokinetic study in the Chinese volunteers. J Pharm Biomed Anal. 2006; 40: 478-83
• 10 Duarte Mendes G, Dantas Sanfelice AT, do Carmo Borges NC, Cavedal LE, Sverdloff C, Prado M et al. Comparative bioavailability of two ramipril formulations after single-dose administration in healthy volunteers. Int J Clin Pharmacol Ther. 2006; 44 (2) 93-8